Cytek Biosciences, Inc. - Common Stock - Nakit Akışı (NASDAQ:CTKB) | MetaTrader

Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit 4.63 M-12.23 M5.28 M25.38 M-4.69 M -7.3 M Yatırım faaliyetlerinden elde edilen nakit -20.99 M-55.91 M-93.89 M-82.97 M10.12 M -26.41 M Finansman faaliyetlerinden elde edilen nakit 213.56 M5.51 M-41.81 M-15.82 M-13.43 M 2.09 M Serbest nakit akışı 4.63 M-12.23 M5.28 M25.38 M-8.88 M -12.84 M

Haberler

Stephens, yüksek maliyetler nedeniyle Cytek hisse hedefini düşürdü

Cytek Biosciences 1Ç 2026’da gelir artışı kaydetti, hisse başına kazanç beklentileri tutmadı

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates

Cytek Biosciences TD Cowen Konferansı’nda Stratejik Büyüme Görünümü

Cytek Biosciences at TD Cowen Health Care: Strategic Growth Insights

Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates

Cytek Biosciences earnings missed by $0.32, revenue topped estimates

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:CTKB) 2026-01-15

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth (CTKB)

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - Beyond Meat (NASDAQ:BYND), Avadel Pharmaceuticals (NASDAQ:AVDL)